Some encounters have big consequences. When QbD’s CEO Bart Van Acker met Antleron co-founder Jan Schrooten at a Flanders.bio event, one thing soon led to another. Though both companies have their characteristics, they both share the ambition to push healthcare forward and make a difference for patients worldwide.
Antleron’s motto ‘engineering life’ says it all. This innovative gang of engineers taps into the huge potential of 3D printing and blends it with the world of biomaterials, biologics, cells, and bioreactors. In doing so, they aim to create life-changing solutions in healthcare.
“Together with QbD, we want to build an ecosystem in which we can jointly do what no one has done before”, Jan explains, “Our research and development matches perfectly with QbD’s tools, skills, and network.”
In other words: QbD can help to turn Antleron’s ‘wild’ ideas into reality. That’s the good thing about this partnership: both companies complement one another in every way – going from scale to competencies – while sharing the same vision of tomorrow’s medical world.
Printing billions of cells
A landslide in healthcare: that’s what QbD and Antleron are going for. What these two companies want to achieve together, is the opposite of the one-size-fits-all approach we often see in medicine today. Every patient now gets the same medicine – in a bigger or smaller dose, but nevertheless. In the future, your pharmacist will print your specific medicine on the spot.
And then there’s the printing with human cells. That sounds like no small feat. However, it’s mere logic, says Jan: “In fact, human cells are nothing more and nothing less than powerful, living building blocks. And you can use them as a raw material for printing personalized body parts or organs. However, we’ll need to know what exactly we want to print.”
It will take a least ten to twenty years before we can 3D-print fully functional organs. “At first, that will be feasible for more simple organs like a liver,” Jan continues, “But whether it will one day be possible to create a functional heart or brain, remains to be seen. In five years, we’ll probably be able to print skin or cartilage tissue. However, we will need to build the capacity to process billions of cells at once to bring this technology into the clinic and make a difference for patients. We still have a very long way to go, in that regard.”
Personalised healthcare solutions for all
This kind of personalized medical solution wouldn’t only serve the happy few. QbD Group and Antleron want to put them within the reach of everyone. “It shouldn’t be something exclusive”, Jan emphasizes, “We want to create the processes and infrastructure to turn it into standard medical practice. You should be able to put a table next to every patient’s bed and print a living spare part for his or her body needs.”
Of course, many steps still need to be taken. Not only scientifically, but also economically, legally, and even ethically.
“The question is whether society is ready for these advanced therapies, as they often require a certain mind switch. It’s something every kind of innovation has to go through. Together we can also face these challenges.” - Bart Van Acker, CEO at QbD Group
Sharing the same vibe
Knowhow and business aside, it’s clear that Antleron and QbD share a strong vibe to make their mark.
Bart: “We both have that openness to fresh views and sharing ideas to make wonderful things happen.”
“It’s easier to make your mark when it really clicks”, Jan adds, “You know what they say: great minds think alike … and sometimes have a drink together! (laughs)”
Get in touch today!
关于作者
Chief Innovation Officer
Martijn is Chief Innovation Officer at QbD Group, spearheading innovation initiatives and digital transformation strategies that keep QbD at the forefront of life sciences consulting.
订阅生命科学领域的最新动态
专家观点直达您的收件箱——选择您的兴趣。
绝无垃圾邮件。随时取消订阅。
